Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and neurological diseases. The adoption of biologics, including monoclonal antibodies and cell therapies, is gaining traction due to their targeted therapeutic approach, fueling demand over conventional drugs. Additionally, the surge in drug development by biotech and pharmaceutical companies, coupled with the growing reliance on contract research organizations (CROs) for faster and more cost-effective discovery services, is further accelerating market growth.
New York, USA, July 30, 2025 (GLOBE NEWSWIRE) -- Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and neurological diseases. The adoption of biologics, including monoclonal antibodies and cell therapies, is gaining traction due to their targeted therapeutic approach, fueling demand over conventional drugs. Additionally, the surge in drug development by biotech and pharmaceutical companies, coupled with the growing reliance on contract research organizations (CROs) for faster and more cost-effective discovery services, is further accelerating market growth.
DelveInsight’s Antibody Discovery Market Insights report provides the current and forecast market analysis, individual leading antibody discovery companies’ market shares, challenges, antibody discovery market drivers, barriers, trends, and key market antibody discovery companies in the market.
Key Takeaways from the Antibody Discovery Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global antibody discovery market during the forecast period.
- In the service type segment of the antibody discovery market, the antibody engineering & optimization category accounted for the largest market share in 2024.
- Notable antibody discovery companies such as Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Biointron Biological Inc., and several others are currently operating in the antibody discovery market.
- In June 2025, Infinimmune, a biotechnology company specializing in human-first antibody discovery and design, launched GLIMPSE-1, a protein language model trained exclusively on native human antibody sequences from millions of paired heavy and light chains of human memory B cells, marking a new approach to therapeutic antibody engineering based on the human adaptive immune system.
- In April 2025, Antibody Solutions announced that single plasma B-cell discovery services have been added to its exclusive Cellestive antibody discovery platform, complementing the existing discovery pathways for activated and memory B-cells.
To read more about the latest highlights related to the antibody discovery market, get a snapshot of the key highlights entailed in the Global Antibody Discovery Market Report
Antibody Discovery Overview
Antibody discovery is a critical process in therapeutic development, aimed at identifying monoclonal antibodies that can specifically target disease-related antigens. The process typically begins with antigen selection and immunization, where animals such as mice are exposed to the target antigen to elicit an immune response. Hybridoma technology, phage display, and more recently, single B-cell cloning and next-generation sequencing (NGS) approaches are employed to isolate and characterize antibody candidates. Advanced in vitro display technologies allow for rapid screening of large antibody libraries, enabling researchers to identify high-affinity and highly specific binders efficiently.
Modern antibody discovery is increasingly driven by computational and AI-based approaches, which accelerate hit identification and optimization. These tools assist in predicting antigen-antibody interactions, improving binding affinity, and minimizing immunogenicity risks. Additionally, humanization techniques and fully human antibody platforms, such as transgenic animals and synthetic libraries, have expanded the therapeutic potential while reducing the likelihood of adverse immune reactions. This combination of wet-lab innovations and computational power has transformed antibody discovery into a faster, more precise, and scalable process, paving the way for next-generation biologics and personalized medicine.
Antibody Discovery Market Insights
North America dominated the antibody discovery market in 2024, supported by several critical factors. This leadership stems from the rising incidence of chronic diseases, significant R&D investments in advanced therapies, increasing demand for biologics, expanded drug development efforts by biotech and pharmaceutical companies, and the adoption of cutting-edge technologies to streamline antibody-based drug creation. These drivers collectively reinforce the region’s strong market position.
Leading players are prioritizing technological innovations to accelerate antibody discovery. For instance, in October 2024, Absci and Twist Bioscience partnered to develop a novel antibody therapeutic by integrating Absci’s generative AI platform with Twist’s synthetic DNA technology. This collaboration combines AI-based antibody design with high-throughput gene synthesis for faster testing and validation.
Overall, the convergence of rising chronic disease prevalence, rapid tech advancements, and strategic research collaborations continues to solidify North America’s role as a key leader in the antibody discovery market.
To know more about why North America is leading the market growth in the antibody discovery market, get a snapshot of the Antibody Discovery Market Outlook
Antibody Discovery Market Dynamics
The antibody discovery market is experiencing robust growth, driven by increasing demand for targeted therapies and personalized medicine. The rising prevalence of chronic and infectious diseases such as cancer, autoimmune disorders, and COVID-19 has accelerated the need for therapeutic antibodies. These molecules are highly specific, making them effective in treating complex diseases with fewer side effects compared to traditional drugs. Additionally, advancements in antibody engineering technologies, including phage display, hybridoma, and next-generation sequencing, have significantly enhanced the speed and efficiency of antibody discovery, further fueling market expansion.
Investment in research and development is another key driver of market dynamics. Biopharmaceutical companies are allocating substantial budgets toward the development of monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs), as these modalities continue to dominate therapeutic pipelines. The growing emphasis on novel modalities such as nanobodies and single-domain antibodies is also reshaping the competitive landscape. Strategic collaborations between biotech firms, academic institutions, and contract research organizations (CROs) are becoming common, facilitating faster innovation cycles and expanding global reach.
Regulatory support and government initiatives are bolstering the market as well. The FDA and EMA have streamlined approval processes for biologics and biosimilars, which has encouraged companies to invest in antibody discovery programs. Additionally, the surge in biosimilar development following patent expirations of blockbuster biologics presents lucrative opportunities for both established and emerging players. However, regulatory compliance and stringent quality standards remain critical challenges that companies must address to maintain competitiveness and ensure patient safety.
Despite strong growth prospects, the antibody discovery market faces several challenges. High development costs, lengthy timelines, and complexities in manufacturing biologics pose significant hurdles for smaller firms. Moreover, the emergence of alternative therapeutic modalities such as gene and cell therapies creates competitive pressures, compelling antibody developers to innovate continuously. Intellectual property issues and supply chain disruptions, especially in the wake of global crises, also add layers of risk to the industry. Nonetheless, technological advancements like AI-driven antibody design, automation, and integration of bioinformatics are expected to overcome many of these bottlenecks, shaping a more efficient and cost-effective discovery landscape.
Looking ahead, the antibody discovery market is poised for transformative growth as precision medicine and immunotherapy continue to gain traction. With an expanding pipeline of antibody-based drugs and increasing adoption in oncology, infectious diseases, and autoimmune conditions, the market is projected to sustain a strong upward trajectory. Emerging trends such as AI-powered discovery platforms, machine learning for epitope prediction, and next-generation sequencing for antibody repertoire analysis will further revolutionize the field, creating new opportunities for innovation and collaboration across the biopharma ecosystem.
Get a sneak peek at the antibody discovery market dynamics @ Antibody Discovery Market Trends
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2022–2032 |
| Antibody Discovery Market CAGR | ~10% |
| Antibody Discovery Market Size by 2032 | ~USD 4 Billion |
| Key Antibody Discovery Companies | Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Biointron Biological Inc., among others |
Antibody Discovery Market Assessment
-
Antibody Discovery Market Segmentation
- Antibody Discovery Market Segmentation By Service Type: Antigen & Epitope Design, Antibody Screening & Selection, Antibody Engineering & Optimization, Antibody Characterization & Validation, and Others
- Antibody Discovery Market Segmentation By Route of Antibody Type: Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and Others
- Antibody Discovery Market Segmentation By Route of Application: Therapeutics, Diagnostics, and Research
- Antibody Discovery Market Segmentation By Route of Source: Human, Humanized, and Others
- Antibody Discovery Market Segmentation By End-User: Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and Others
- Antibody Discovery Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the antibody discovery market are set to emerge as the trendsetter explore @ Antibody Discovery Analysis
Table of Contents
| 1 | Antibody Discovery Market Report Introduction |
| 2 | Antibody Discovery Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Antibody Discovery Market Key Factors Analysis |
| 6 | Antibody Discovery Market Porter’s Five Forces Analysis |
| 7 | Antibody Discovery Market Layout |
| 8 | Antibody Discovery Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the antibody discovery market by 2032? Click to get a snapshot of the Antibody Discovery Market Analysis
Related Reports
Monoclonal Antibody Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key monoclonal antibody companies, including Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, Novo Nordisk, Merck KGaA, Bristol-Myers Squibb, Jacobio Pharmaceuticals, among others.
Contract Development Manufacturing Organization Market
Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, among others.
Biopharmaceuticals Contract Manufacturing Market
Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.
Biologics Drug Substance Fill and Finish Manufacturing Market
Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, among others.
Biologics Drug Substance Manufacturing Market
Biologics Drug Substance Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance manufacturing companies, including Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A/S, Siegfried Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD., FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific, among others.
Biologics Contract Manufacturing Market
Biologics Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biologics contract manufacturing companies, including Boehringer Ingelheim, Catalent, Lonza, WuXi Biologics, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie, AGC Biologics, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
